Comparative Pharmacology
Head-to-head clinical analysis: ALOGLIPTIN versus SITAGLIPTIN METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOGLIPTIN versus SITAGLIPTIN METFORMIN HYDROCHLORIDE.
ALOGLIPTIN vs SITAGLIPTIN; METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alogliptin is a selective, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4). By inhibiting DPP-4, it increases the levels of active incretin hormones (GLP-1 and GIP), which stimulate insulin secretion in a glucose-dependent manner and suppress glucagon release, thereby improving glycemic control.
Sitagliptin is a DPP-4 inhibitor that increases incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion and reducing glucagon secretion. Metformin is a biguanide that decreases hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity via AMP-kinase activation.
25 mg orally once daily
1 tablet orally twice daily; each tablet contains sitagliptin 50 mg and metformin hydrochloride 500 mg, 850 mg, or 1000 mg; maximum dose: sitagliptin 100 mg/day, metformin 2000 mg/day.
None Documented
None Documented
Clinical Note
moderateAlogliptin + Gatifloxacin
"Alogliptin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateAlogliptin + Rosoxacin
"Alogliptin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateAlogliptin + Levofloxacin
"Alogliptin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateAlogliptin + Trovafloxacin
"Alogliptin may increase the hypoglycemic activities of Trovafloxacin."
Terminal elimination half-life is approximately 12-21 hours. This supports once-daily dosing. In patients with renal impairment, half-life is prolonged (e.g., up to 32 hours in severe impairment), necessitating dose adjustment.
Sitagliptin: terminal half-life 12.4 hours (healthy), prolonged in renal impairment (up to 28–39 hours in severe impairment). Metformin: terminal half-life 4–8.7 hours (healthy), prolonged in renal impairment (up to 17.6 hours in moderate impairment).
Approximately 60-71% of the dose is excreted unchanged in urine via active renal tubular secretion, with about 20% eliminated as metabolites (primarily N-demethylated and N-acetylated derivatives) in urine, and less than 2% in feces. Renal excretion is the major route.
Sitagliptin: 79% excreted unchanged in urine via renal tubular secretion and glomerular filtration; 13% metabolized with 4% excreted in feces. Metformin: 90% excreted unchanged in urine via glomerular filtration and tubular secretion; <5% in feces.
Category C
Category A/B
DPP-4 Inhibitor
DPP-4 Inhibitor